Carregant...
Targeted therapy for idiopathic pulmonary fibrosis: where to now?
Idiopathic pulmonary fibrosis (IPF) is an aging-associated recalcitrant lung disease with historically limited therapeutic options. The recent approval of two drugs, pirfenidone and nintedanib, by the United States Food and Drug Administration (FDA) in 2014 has heralded a new era in its management....
Guardat en:
| Publicat a: | Drugs |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4939080/ https://ncbi.nlm.nih.gov/pubmed/26729185 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-015-0523-6 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|